The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are
usually older than 45 years and their main demand is to treat pre-existing facial wrinkles.
However with the increasing popularity of this technique, younger patients, aged 25 to 35
years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The
usual dose used for the treatment of facial rhytides in a female patient older than 45 years
is 50 units. No consensus exists concerning the dose of botulinum toxin that should be used
in younger patients. Hypothesis: lower dose of botulinum toxin is sufficient to give good and
long lasting results in young patients. The objective of this randomized open-label study is
to evaluate the effect of lower doses of Botulinum toxin on the facial rythides in young
patients.